Brian McNamara Sells 704,974 Shares of Haleon (LON:HLN) Stock

Haleon plc (LON:HLN) insider Brian McNamara sold 704,974 shares of Haleon stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of GBX 368, for a total transaction of £2,594,304.32.

Brian McNamara also recently made the following trade(s):

• On Monday, March 23rd, Brian McNamara sold 63,012 shares of Haleon stock. The stock was sold at an average price of GBX 368, for a total value of £231,884.16.

Haleon Stock Performance

HLN traded down GBX 8.30 on Tuesday, hitting GBX 357.30. The company had a trading volume of 142,630,016 shares, compared to its average volume of 38,006,121. The company’s fifty day moving average price is GBX 385.90 and its 200 day moving average price is GBX 367.45. Haleon plc has a 1-year low of GBX 325.10 and a 1-year high of GBX 419.50. The company has a debt-to-equity ratio of 52.26, a current ratio of 0.92 and a quick ratio of 0.93. The stock has a market cap of £31.82 billion, a price-to-earnings ratio of 19.31, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25.

Haleon (LON:HLN) last announced its quarterly earnings results on Thursday, February 26th. The company reported GBX 18.60 EPS for the quarter. Haleon had a return on equity of 9.44% and a net margin of 13.81%. Equities analysts predict that Haleon plc will post 19.5033282 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HLN has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a report on Thursday, January 22nd. JPMorgan Chase & Co. raised their price target on Haleon from GBX 315 to GBX 335 and gave the company an “underweight” rating in a research report on Wednesday, November 26th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 450 price objective on shares of Haleon in a research note on Wednesday, January 21st. Finally, Berenberg Bank increased their target price on Haleon from GBX 510 to GBX 512 and gave the company a “buy” rating in a research note on Thursday, March 19th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of GBX 407.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.